CA2208924A1 - Utilisation reduite de paclitaxel grace a l'hyaluronan - Google Patents

Utilisation reduite de paclitaxel grace a l'hyaluronan

Info

Publication number: CA2208924A1
Authority: CA; Canada
Prior art keywords: amount; hyaluronan; paclitaxel; dosage amount; less
Prior art date: 1997-07-09
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002208924A

Other languages

English (en)

Inventor

Adrian Moore

Samuel S. Asculai

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Jagotec AG

Original Assignee

Hyal Pharmaceutical Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-07-09

Filing date

1997-07-09

Publication date

1999-01-09

1997-07-09 Application filed by Hyal Pharmaceutical Corp filed Critical Hyal Pharmaceutical Corp

1997-07-09 Priority to CA002208924A priority Critical patent/CA2208924A1/fr

1998-07-08 Priority to AU82031/98A priority patent/AU8203198A/en

1998-07-08 Priority to PCT/CA1998/000660 priority patent/WO1999002151A1/fr

1999-01-09 Publication of CA2208924A1 publication Critical patent/CA2208924A1/fr

Status Abandoned legal-status Critical Current

Links

229920002674 hyaluronan Polymers 0.000 title claims abstract description 69
229940099552 hyaluronan Drugs 0.000 title claims abstract description 51
KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 title claims abstract description 50
229930012538 Paclitaxel Natural products 0.000 title claims abstract description 49
229960001592 paclitaxel Drugs 0.000 title claims abstract description 49
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 title claims abstract description 49
239000003814 drug Substances 0.000 claims abstract description 10
KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 18
229960003160 hyaluronic acid Drugs 0.000 claims description 18
238000011282 treatment Methods 0.000 claims description 17
150000003839 salts Chemical class 0.000 claims description 11
108090000623 proteins and genes Proteins 0.000 claims description 9
102000004169 proteins and genes Human genes 0.000 claims description 9
230000001575 pathological effect Effects 0.000 claims description 7
238000000034 method Methods 0.000 claims description 6
238000004519 manufacturing process Methods 0.000 claims description 3
102000018866 Hyaluronan Receptors Human genes 0.000 claims description 2
108010013214 Hyaluronan Receptors Proteins 0.000 claims description 2
239000008194 pharmaceutical composition Substances 0.000 claims 3
201000010099 disease Diseases 0.000 claims 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
239000000546 pharmaceutical excipient Substances 0.000 claims 2
206010028980 Neoplasm Diseases 0.000 abstract description 15
239000003795 chemical substances by application Substances 0.000 abstract description 9
201000011510 cancer Diseases 0.000 abstract description 6
YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 9
229920002385 Sodium hyaluronate Polymers 0.000 description 8
239000000203 mixture Substances 0.000 description 8
229940010747 sodium hyaluronate Drugs 0.000 description 8
238000012360 testing method Methods 0.000 description 8
239000000243 solution Substances 0.000 description 7
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
150000001875 compounds Chemical class 0.000 description 6
239000008389 polyethoxylated castor oil Substances 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
230000001225 therapeutic effect Effects 0.000 description 5
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
230000008033 biological extinction Effects 0.000 description 4
239000002158 endotoxin Substances 0.000 description 4
239000008187 granular material Substances 0.000 description 4
238000002347 injection Methods 0.000 description 4
239000007924 injection Substances 0.000 description 4
238000001990 intravenous administration Methods 0.000 description 4
239000000843 powder Substances 0.000 description 4
238000003556 assay Methods 0.000 description 3
229940079593 drug Drugs 0.000 description 3
230000000694 effects Effects 0.000 description 3
238000009472 formulation Methods 0.000 description 3
229910001385 heavy metal Inorganic materials 0.000 description 3
230000002209 hydrophobic effect Effects 0.000 description 3
230000000813 microbial effect Effects 0.000 description 3
244000005700 microbiome Species 0.000 description 3
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
239000008223 sterile water Substances 0.000 description 3
231100000331 toxic Toxicity 0.000 description 3
230000002588 toxic effect Effects 0.000 description 3
MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 2
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
229920002683 Glycosaminoglycan Polymers 0.000 description 2
102100023122 Glycylpeptide N-tetradecanoyltransferase 2 Human genes 0.000 description 2
101710081889 Glycylpeptide N-tetradecanoyltransferase 2 Proteins 0.000 description 2
OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 2
OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 2
MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 2
240000004808 Saccharomyces cerevisiae Species 0.000 description 2
239000000061 acid fraction Substances 0.000 description 2
IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 2
150000001413 amino acids Chemical class 0.000 description 2
239000002246 antineoplastic agent Substances 0.000 description 2
229910052785 arsenic Inorganic materials 0.000 description 2
RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 2
MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 2
230000002939 deleterious effect Effects 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
238000001035 drying Methods 0.000 description 2
229960002442 glucosamine Drugs 0.000 description 2
229940097043 glucuronic acid Drugs 0.000 description 2
238000002329 infrared spectrum Methods 0.000 description 2
229910052742 iron Inorganic materials 0.000 description 2
229950006780 n-acetylglucosamine Drugs 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
239000013618 particulate matter Substances 0.000 description 2
235000019624 protein content Nutrition 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
239000013557 residual solvent Substances 0.000 description 2
159000000000 sodium salts Chemical class 0.000 description 2
238000001228 spectrum Methods 0.000 description 2
229940124597 therapeutic agent Drugs 0.000 description 2
230000000699 topical effect Effects 0.000 description 2
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
238000011725 BALB/c mouse Methods 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
108010003272 Hyaluronate lyase Proteins 0.000 description 1
102000001974 Hyaluronidases Human genes 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 1
241000589517 Pseudomonas aeruginosa Species 0.000 description 1
241000191967 Staphylococcus aureus Species 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229940034982 antineoplastic agent Drugs 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
239000005388 borosilicate glass Substances 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
229910002092 carbon dioxide Inorganic materials 0.000 description 1
230000015271 coagulation Effects 0.000 description 1
238000005345 coagulation Methods 0.000 description 1
239000006071 cream Substances 0.000 description 1
229940127089 cytotoxic agent Drugs 0.000 description 1
230000001627 detrimental effect Effects 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
239000005308 flint glass Substances 0.000 description 1
230000005484 gravity Effects 0.000 description 1
230000012010 growth Effects 0.000 description 1
229960002773 hyaluronidase Drugs 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000036512 infertility Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
239000007788 liquid Substances 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
239000000463 material Substances 0.000 description 1
QUANRIQJNFHVEU-UHFFFAOYSA-N oxirane;propane-1,2,3-triol Chemical compound C1CO1.OCC(O)CO QUANRIQJNFHVEU-UHFFFAOYSA-N 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
239000002245 particle Substances 0.000 description 1
238000011084 recovery Methods 0.000 description 1
238000009781 safety test method Methods 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
229940049529 sodium hyaluronate 20 mg/ml Drugs 0.000 description 1
239000008174 sterile solution Substances 0.000 description 1
230000001629 suppression Effects 0.000 description 1
231100000820 toxicity test Toxicity 0.000 description 1
231100000041 toxicology testing Toxicity 0.000 description 1
230000004614 tumor growth Effects 0.000 description 1
239000003981 vehicle Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Dermatology (AREA)
Inorganic Chemistry (AREA)
Molecular Biology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

CA002208924A 1997-07-09 1997-07-09 Utilisation reduite de paclitaxel grace a l'hyaluronan Abandoned CA2208924A1 (fr)

Priority Applications (3)

Application Number	Priority Date	Filing Date	Title
CA002208924A CA2208924A1 (fr)	1997-07-09	1997-07-09	Utilisation reduite de paclitaxel grace a l'hyaluronan
AU82031/98A AU8203198A (en)	1997-07-09	1998-07-08	Paclitaxel compositions containing hyaluronic acid of a molecular weight of lessthan 750.000 da
PCT/CA1998/000660 WO1999002151A1 (fr)	1997-07-09	1998-07-08	Compositions de paclitaxel contenant un acide hyaloronique de poids moleculaire inferieur a 750 000 da

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CA002208924A CA2208924A1 (fr)	1997-07-09	1997-07-09	Utilisation reduite de paclitaxel grace a l'hyaluronan

Publications (1)

Publication Number	Publication Date
CA2208924A1 true CA2208924A1 (fr)	1999-01-09

Family

ID=4160954

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002208924A Abandoned CA2208924A1 (fr)	1997-07-09	1997-07-09	Utilisation reduite de paclitaxel grace a l'hyaluronan

Country Status (3)

Country	Link
AU (1)	AU8203198A (fr)
CA (1)	CA2208924A1 (fr)
WO (1)	WO1999002151A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2002534484A (ja) *	1999-01-13	2002-10-15	メディテックリサーチリミテッド	薬物の効力を増強するための組成物および方法
US8287894B2 (en)	2000-07-14	2012-10-16	Alchemia Oncology Pty Limited	Hyaluronan as a drug pre-sensitizer and chemo-sensitizer in the treatment of disease
US8623354B2 (en)	2005-09-07	2014-01-07	Alchemia Oncology Pty Limited	Therapeutic compositions comprising hyaluronan and therapeutic antibodies as well as methods of treatment
US8937052B2 (en)	2005-07-27	2015-01-20	Alchemia Oncology Pty Limited	Therapeutic protocols using hyaluronan
US9066919B2 (en)	2000-07-14	2015-06-30	Alchemia Oncology Pty Limited	Hyaluronan as a chemo-sensitizer in the treatment of cancer

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6593308B2 (en) *	1999-12-03	2003-07-15	The Regents Of The University Of California	Targeted drug delivery with a hyaluronan ligand
DK1250152T3 (da)	1999-12-28	2013-08-26	Bioniche Urology Ip Inc	Synergistisk sammensætning indeholdende hyaluronsyre til behandling af cancer
IT1318403B1 (it)	2000-03-17	2003-08-25	Cooperativa Ct Ricerche Poly T	Esteri polisaccaridici di n-derivati di acido glutammico.
ITPD20020271A1 (it) *	2002-10-18	2004-04-19	Fidia Farmaceutici	Composti chimico-farmaceutici costituiti da derivati dei taxani legati covalentemente all'acido ialuronico o ai suoi derivati.
AU2003284885A1 (en)	2002-10-21	2004-05-13	Kensey Nash Corporation	Device and methods for sequential, regional delivery of multiple cytotoxic agents
US8088605B2 (en)	2002-12-04	2012-01-03	Technologies Biolactics Inc.	Exopolysaccharides delivery system for active molecules
LT2543357T (lt) *	2011-07-07	2018-06-11	Holy Stone Healthcare Co.,Ltd.	Kompozicija, skirta panaudoti su uždegimu susijusių susirgimų gydymui arba prevencijai

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE8900422D0 (sv) *	1989-02-08	1989-02-08	Pharmacia Ab	Tvaerbundna hyaluronatgeler samt foerfarande foer framstaellning av dessa
CA2122519C (fr) *	1994-04-29	2001-02-20	Rudolf Edgar Dr. Falk	Traitement du cancer et prevention des metastases
WO1993024476A1 (fr) *	1992-06-04	1993-12-09	Clover Consolidated, Limited	Vehicules polymeres solubles dans l'eau servant a la liberation de medicaments
SE9301422D0 (sv) *	1993-04-28	1993-04-28	Kabi Pharmacia Ab	Method and means for inhibiting posterior capsule opacification

1997
- 1997-07-09 CA CA002208924A patent/CA2208924A1/fr not_active Abandoned
1998
- 1998-07-08 AU AU82031/98A patent/AU8203198A/en not_active Abandoned
- 1998-07-08 WO PCT/CA1998/000660 patent/WO1999002151A1/fr not_active Ceased

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2002534484A (ja) *	1999-01-13	2002-10-15	メディテックリサーチリミテッド	薬物の効力を増強するための組成物および方法
JP4790911B2 (ja) *	1999-01-13	2011-10-12	アルケミアオンコロジーピーティワイリミテッド	薬物の効力を増強するための組成物および方法
US8741970B2 (en)	1999-01-13	2014-06-03	Alchemia Oncology Pty Limited	Composition and method for the enhancement of the efficacy of drugs
US8287894B2 (en)	2000-07-14	2012-10-16	Alchemia Oncology Pty Limited	Hyaluronan as a drug pre-sensitizer and chemo-sensitizer in the treatment of disease
US8388993B2 (en)	2000-07-14	2013-03-05	Alchemia Oncology Pty Limited	Hyaluronan-chemotherapeutic agent formulations for the treatment of colon cancer
US9066919B2 (en)	2000-07-14	2015-06-30	Alchemia Oncology Pty Limited	Hyaluronan as a chemo-sensitizer in the treatment of cancer
US8937052B2 (en)	2005-07-27	2015-01-20	Alchemia Oncology Pty Limited	Therapeutic protocols using hyaluronan
US8623354B2 (en)	2005-09-07	2014-01-07	Alchemia Oncology Pty Limited	Therapeutic compositions comprising hyaluronan and therapeutic antibodies as well as methods of treatment

Also Published As

Publication number	Publication date
AU8203198A (en)	1999-02-08
WO1999002151A1 (fr)	1999-01-21

Publication	Publication Date	Title
US6537978B1 (en)	2003-03-25	Oral administration of effective amounts of forms of hyaluronic acid
US6475795B1 (en)	2002-11-05	Use of hyaluronan in gene therapy
CA2122519C (fr)	2001-02-20	Traitement du cancer et prevention des metastases
US5614506A (en)	1997-03-25	Use of hyaluronic acid and forms to prevent arterial restenosis
US20130143839A1 (en)	2013-06-06	Cystitis treatment with high dose chondroitin sulfate
CA2208924A1 (fr)	1999-01-09	Utilisation reduite de paclitaxel grace a l'hyaluronan
WO1996006622A1 (fr)	1996-03-07	Acide hyaluronique et derives destines a la modulation de l'activite cellulaire
US5674857A (en)	1997-10-07	Use of hyaluronic acid to repair ischemia reperfusion damage
CA2175282A1 (fr)	1997-10-30	Utilisation de diverses formes d'acide hyaluronique (ah) pour le traitement du cancer
AP619A (en)	1997-10-10	Use of hyaluronic acid or salt for the treatment of a human having a stroke or myocardial infarction.
US5817642A (en)	1998-10-06	Clearing of atherosclerosis
JP4210330B2 (ja)	2009-01-14	ヒアルロン酸レセプター結合剤、およびその使用方法
SA97180188B1 (ar)	2006-08-06	تركيب وطريقة تحضير الكاربابنيم كمضاد حيوي
US5817644A (en)	1998-10-06	Targeting of dosages of medicine and therapeutic agents
RS50523B (sr)	2010-05-07	Farmaceutska kompozicija koja sadrži cink-hijaluronat kompleks za lečenje multiple skleroze
EP0758246A1 (fr)	1997-02-19	Composition pharmaceutique comprenant de l'acide hyaluronique et destinee a eliminer l'arteriosclerose
CA2131130A1 (fr)	1996-03-01	Modulation de l'activite cellulaire
CA2164260C (fr)	2001-10-09	Methode de ciblage pour medicaments et agents therapeutiques
DE69634993T2 (de)	2006-04-20	Verwendung von hyaluronan in gentherapie
EA041409B1 (ru)	2022-10-20	Фармацевтическое средство для лечения артрологических заболеваний
HK1005984A (en)	1999-02-05	The use of hyaluronic acid to repair ischemia reperfusion damage
Summersgill et al.	1984	Azlocillin and cefonicid penetration into bone enhanced by probenecid

Legal Events

Date	Code	Title	Description
1997-07-09	EEER	Examination request
2000-07-10	FZDE	Dead